157 related articles for article (PubMed ID: 4720804)
1. Imuran-induced regression of plasma cell tumor MOPC-315.
Schlossberg M; Hollander VP
Cancer Res; 1973 Aug; 33(8):1953-6. PubMed ID: 4720804
[No Abstract] [Full Text] [Related]
2. Transplantable mouse plasma cell tumors in experimental chemotherapy.
Teller MN; Abraham D; Bowie M; Carbone PP
J Natl Cancer Inst; 1969 Jul; 43(1):123-31. PubMed ID: 5816022
[No Abstract] [Full Text] [Related]
3. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
[No Abstract] [Full Text] [Related]
4. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.
Hiramoto RN; Ghanta VK
Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918
[No Abstract] [Full Text] [Related]
5. The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors.
Schabel FM
Cancer Res; 1969 Dec; 29(12):2384-9. PubMed ID: 5369685
[No Abstract] [Full Text] [Related]
6. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine.
Gardiner SJ; Begg EJ; Barclay ML; Kirkpatrick CM
Adverse Drug React Toxicol Rev; 2000 Dec; 19(4):293-312. PubMed ID: 11212460
[No Abstract] [Full Text] [Related]
7. [Immunosuppressive treatment in renal homologous transplantation].
Mazzei D; Vallino F; Civardi F
Minerva Chir; 1975 Aug 15-31; 30(15-16):866-73. PubMed ID: 772470
[No Abstract] [Full Text] [Related]
8. When is too much enough?
Mayer L
Gastroenterology; 2006 Apr; 130(4):1352-4. PubMed ID: 16618427
[No Abstract] [Full Text] [Related]
9. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Hiramoto R; Ghanta V; Durant JR
Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
[TBL] [Abstract][Full Text] [Related]
10. [Immunosuppressive therapy].
Melli G
Recenti Prog Med; 1970 Jan; 48(1):1-18. PubMed ID: 4910156
[No Abstract] [Full Text] [Related]
11. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
12. Factor XIII deficiency in BALB/c mice with plasmacytoma.
Eipe J; Yakulis V; Costea N
Cancer Res; 1977 Oct; 37(10):3551-5. PubMed ID: 908006
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of cancer cell kill by chemotherapeutic agents in vivo.
Wilcox WS
Natl Cancer Inst Monogr; 1967 Feb; 24():257-69. PubMed ID: 6021080
[No Abstract] [Full Text] [Related]
14. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN
Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251
[TBL] [Abstract][Full Text] [Related]
15. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.
Teller MN; Bowie M; Mountain IM; Stock CC
J Natl Cancer Inst; 1974 Mar; 52(3):667-71. PubMed ID: 4857022
[No Abstract] [Full Text] [Related]
17. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
Su C; Lichtenstein GR
Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
[TBL] [Abstract][Full Text] [Related]
18. Association of host immunity with 5-fluorouracil-initiated cure of plasmacytoma LPC-1 in BALB/c mice.
Teller MN; Faanes RB
Cancer Res; 1980 Aug; 40(8 Pt 1):2790-5. PubMed ID: 6966969
[No Abstract] [Full Text] [Related]
19. [Childhood nephrotic syndrome with minimun glomerular lesions (clinical development and therapeutic response in 40 cases)].
Ruilope LM; Casado S; López de Novales E; Barat A; Alvarez J; Hernando L
Rev Clin Esp; 1973 Nov; 131(4):313-8. PubMed ID: 4772782
[No Abstract] [Full Text] [Related]
20. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
